公开(公告)号：US11572374B2

公开(公告)日：2023-02-07

申请号：US17266466

申请日：2019-08-13

Applicant: Amgen Inc. ,  Carmot Therapeutics, Inc.

Inventor： John R. Butler ,  Daniel Erlanson ,  Russell Graceffa ,  Jeffrey Iwig ,  Joon Won Jeong ,  Ryan D. White ,  Yongwei Wu ,  Shuyan Yi ,  Xiao Mei Zheng ,  Jesse M. McFarland ,  Abhisek Banerjee

IPC: C07D519/00 ,  C07D487/18

Abstract: The present invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof, pharmaceutical compositions comprising a compound of the invention, a method for manufacturing compounds of the invention and therapeutic uses thereof.

公开(公告)号：US09212182B2

公开(公告)日：2015-12-15

申请号：US14302337

申请日：2014-06-11

Applicant: AMGEN INC.

Inventor： Matthew Weiss ,  Alessandro Boezio ,  Christiane Boezio ,  John R. Butler ,  Margaret Yuhua Chu-Moyer ,  Erin F. Dimauro ,  Thomas Dineen ,  Russell Graceffa ,  Angel Guzman-Perez ,  Hongbing Huang ,  Charles Kreiman ,  Daniel La ,  Isaac E. Marx ,  Benjamin Charles Milgrim ,  Hanh Nho Nguyen ,  Emily Peterson ,  Karina Romero ,  Brian Sparling

IPC: A61K31/00 ,  C07D215/00 ,  C07D471/04 ,  C07D413/12 ,  C07D401/12 ,  C07D413/14 ,  C07D417/12 ,  C07C53/18 ,  C07D215/227 ,  C07D403/12 ,  C07D215/36 ,  C07D241/44

CPC classification number: C07D417/14 ,  C07C53/18 ,  C07D215/227 ,  C07D215/36 ,  C07D241/44 ,  C07D401/12 ,  C07D401/14 ,  C07D403/12 ,  C07D413/12 ,  C07D413/14 ,  C07D417/12 ,  C07D471/04

Abstract: The present invention provides compounds of Formula I, and pharmaceutically acceptable salts thereof, that are inhibitors of voltage-gated sodium channels, in particular Nav1.7. The compounds are useful for the treatment of diseases associated with the activity of sodium channels such as pain disorders and itch. Also provided are pharmaceutical compositions containing compounds of the present invention.

Abstract translation: 本发明提供式I化合物及其药学上可接受的盐，其是电压门控钠通道的抑制剂，特别是Nav1.7。 该化合物可用于治疗与钠通道活性相关的疾病，例如疼痛障碍和瘙痒。 还提供含有本发明化合物的药物组合物。

公开(公告)号：US11845760B2

公开(公告)日：2023-12-19

申请号：US17552016

申请日：2021-12-15

Applicant: AMGEN INC.

Inventor： Shon Booker ,  Matthew Paul Bourbeau ,  John R. Butler ,  Sanne Ormholt Schroder Glad ,  Brian Alan Lanman ,  Patricia Lopez ,  Francesco Manoni ,  Liping H. Pettus ,  Ian Sarvary ,  Nuria A. Tamayo ,  Mikkel Vestergaard ,  Nicholas Anthony Weires

IPC: C07D471/04 ,  C07D471/14 ,  C07D491/04 ,  C07D491/14 ,  C07D495/04 ,  A61K31/4355 ,  A61K31/436 ,  A61K31/4365 ,  A61K31/437 ,  A61K31/4375 ,  A61P35/00 ,  C07D491/06 ,  C07D471/06 ,  C07D471/16 ,  C07D491/16

CPC classification number: C07D491/06 ,  A61P35/00 ,  C07D471/06 ,  C07D471/16 ,  C07D491/16

Abstract: Described herein are novel PRMT5 inhibitors of Formula I and pharmaceutically acceptable salts thereof, as well as the pharmaceutical compositions thereof. Compounds of the present invention are useful for inhibiting PRMT5 activity and may have use in treating proliferative, metabolic and blood disorders. Compounds of Formula I have the following structure:

公开(公告)号：US09458152B2

公开(公告)日：2016-10-04

申请号：US14920833

申请日：2015-10-22

Applicant: AMGEN INC.

Inventor： Matthew Weiss ,  Alessandro Boezio ,  Christiane Boezio ,  John R. Butler ,  Margaret Yuhua Chu-Moyer ,  Erin F. Dimauro ,  Thomas Dineen ,  Russell Graceffa ,  Angel Guzman-Perez ,  Hongbing Huang ,  Charles Kreiman ,  Daniel La ,  Isaac E. Marx ,  Benjamin Charles Milgram ,  Hanh Nho Nguyen ,  Emily Anne Peterson ,  Karina R. Vaida ,  Brian Sparling

IPC: A61K31/00 ,  C07D417/14 ,  C07D471/04 ,  C07D413/12 ,  C07D401/12 ,  C07D413/14 ,  C07D417/12 ,  C07C53/18 ,  C07D215/227 ,  C07D403/12 ,  C07D215/36 ,  C07D241/44 ,  C07D401/14

CPC classification number: C07D417/14 ,  C07C53/18 ,  C07D215/227 ,  C07D215/36 ,  C07D241/44 ,  C07D401/12 ,  C07D401/14 ,  C07D403/12 ,  C07D413/12 ,  C07D413/14 ,  C07D417/12 ,  C07D471/04

Abstract: The present invention provides compounds of Formula I, and pharmaceutically acceptable salts thereof, that are inhibitors of voltage-gated sodium channels, in particular Nav1.7. The compounds are useful for the treatment of diseases associated with the activity of sodium channels such as pain disorders and itch. Also provided are pharmaceutical compositions containing compounds of the present invention.

公开(公告)号：US10668067B2

公开(公告)日：2020-06-02

申请号：US16319783

申请日：2017-07-20

Applicant: AMGEN INC.

Inventor： Matthew Weiss ,  John R. Butler ,  Benjamin Charles Milgram ,  Gwenaella Rescourio ,  Alessandro Boezio ,  Brian Andrew Sparling ,  Daniel La

IPC: A61K31/506 ,  A61K31/4439 ,  A61P25/00 ,  C07D213/75 ,  C07D401/12 ,  C07D413/12 ,  C07D417/12

Abstract: The present invention provides compounds of Formula (I), as defined in the specification, or pharmaceutically acceptable salts thereof, that are inhibitors of voltage-gated sodium channels, in particular Nav 1.7. The compounds are useful for the treatment of diseases treatable by inhibition of sodium channels such as pain disorders, cough, or itch. Also provided are pharmaceutical compositions containing compounds of the present invention.